TuHURA Biosciences, Inc. (HURA)
TuHURA Biosciences develops experimental cancer treatments for patients whose tumors resist immunotherapy, based in Tampa, Florida. It last closed at $1.40 on Nov 17, up 5.26% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From HURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 18 | Citizens | Reiterated | Buy | $9 |
| Apr 27 | Citizens | Initiated | Buy | $9 |
Technical Analysis
The stock is 25% below its 20 day and 35% below its 50 day average. It is 45% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $1.38, and the nearest resistance the Pivot R1 at $1.45.
| RSI (14) | 34.69 | Weak, oversold below 30 | Neutral |
| MACD | -0.15 | Below its signal line | Bearish |
| Stochastic | 9.0 | Near the bottom of its range | Oversold |
| ADX (14) | 21.8 | Weak trend | |
| Williams %R | -84.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -112.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −15.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.16 | Typical daily range, 11.3% of price |
| RSI (14) | 39.16 | Weak, oversold below 30 | Neutral |
| MACD | -0.13 | Below its signal line | Bearish |
| Stochastic | 6.7 | Near the bottom of its range | Oversold |
| ADX (14) | 23.1 | Weak trend | |
| Williams %R | -89.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -234.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −31.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.35 | Typical daily range, 24.9% of price |
What happened before
See how HURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How HURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in HURA in the last 90 days.
HURA Institutional Ownership
Full report →- ▼19 buying vs 57 selling
- ▼Held by funds -3.7 pts
- ▼Funds holding -13
- ▼Superinvestors: 0 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 77 | 90 | −14.4% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 10.0% | 13.7% | −3.7 pts |
| New / increased | 7 / 12 | 24 / 16 | −52.5% |
| Reduced / sold out | 39 / 18 | 32 / 21 | +7.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HURA is in one of them and how their past HURA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered HURA in an article yet. Here's the latest on the wider market.
HURA Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Laurel LeeR · FL | Buy | $50K – $100K | Jul 13, 2025 | Aug 9, 2025 | 27 d |
| Laurel LeeR · FL | Buy | $1K – $15K | Nov 25, 2024 | Jan 7, 2025 | 43 d |
| Laurel LeeR · FL | Buy | $100K – $250K | Oct 18, 2024 | Nov 21, 2024 | 34 d |
| Laurel LeeR · FL | Exchange | $100K – $250K | Oct 18, 2024 | Nov 21, 2024 | 34 d |
| Laurel LeeR · FL | Buy | $100K – $250K | May 6, 2024 | May 25, 2024 | 19 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About TuHURA Biosciences
TuHURA Biosciences is a clinical stage company based in Tampa, Florida, that develops cancer treatments. Its lead candidate, IFx-2.0, is injected into tumors and is designed to make cancer cells look like bacteria so the immune system attacks them. It is aimed at patients whose cancers do not respond to checkpoint inhibitor drugs. The company is also developing TBS-2025, an antibody for acute myeloid leukemia, and early-stage drugs that target cells which suppress the immune system. Its candidates are not yet approved for sale.
- Headquarters
- Tampa, FL


